Opioid UseNCT03678870
Discharge Opioid Education to Decrease Opioid Use After Cesarean
A study testing Opioid Education Handout in people with Opioid Use, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Opioid Use
- What is being tested?
- Opioid Education Handout
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 196 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2018to 1 Nov 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Women 18-45 years old
- Women undergoing cesarean delivery at VUMC
Who cannot join
- Major post-surgical complications:
- cesarean hysterectomy, bowel or bladder injury, reoperation, ICU admission, wound infection or separation
- Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for > 7 days during pregnancy.
- Women who do not speak English
Trial locations and contacts
1 site in 1 country.
About this study
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.
Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge
Read the detailed description
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.
Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge
Preliminary Data: Our soon to be published study (Obstetrics \& Gynecology Journal) found that 30% of women used all their opioids after discharge for cesarean delivery because they "were following directions" and not because they had pain.
Enrollment \& Randomization
Enrollment
- Participants will be approached after their cesarean delivery either in the recovery room or in their private postpartum room
- Informed written consent will be obtained by a trained research assistant (i.e. medical student) or by the study researchers (Attendings, fellows)
- After enrollment, participants will be asked to complete Survey 1 either in person or by giving sending them the web link with RedCap
Randomization
- Enrolled patients will be randomized in a 1:1 ratio using permuted blocks of 6
- Randomization sequence will be developed through sealed envelope.com
- Randomization and allocation will be done through RedCap
Study Procedures
- Enrollment
- Postoperative Day 0-1: Survey 1 through RedCap (takes ~10 minutes)
- Randomization education versus usual care
- Control = Standard discharge instructions, which list medications prescribed at discharge
- Intervention = a single page handout (see attachment) with information about how to use medications for pain after discharge. This handout contains the following instructions
- Get baseline pain control with ibuprofen
- Use your opioid prescription only if your pain is very bad
- Taper your medications
- Get rid of leftover opioid tablets
- At discharge all patients will receive the follow medications using PillsyCaps. These are standard medications given at discharge at our institution
- Ibuprofen 600mg: 30 tablets
- Hydrocodone 5mg -acetaminophen 325mg: 30 tablets
- Postoperative day 14: All participants will be contacted to complete Survey 2 (Takes ~ 15 minutes
- Attempts to contact each participant will be done 3 times before they are designated as "lost to follow up"
- If a participant is still using opioids on postoperative day 14, they should be contacted weekly until they are no longer taking opioids
Primary Outcome Median number of tablets of hydrocodone-acetaminophen used after hospital discharge
Secondary Outcomes:
- Visual Analog Scale pain score (median)
- Percentage of patients reporting pain since discharge as worse than expected
- Percentage of patients obtaining additional prescriptions for pain
- Percentage of patients with unscheduled visits for pain
- Mean ibuprofen milligrams used hours 24-47 after cesarean
- Mean acetaminophen milligrams used hours 24-47 after cesarean
- Total Morphine Milligram Equivalents (MME) used per hour of inpatient stay
Risks
- Breach of confidentiality of protected health information
Reporting Adverse Events Any adverse events or unanticipated problems involving risk to participants or others will be reported to the Institutional Review Board and the Vanderbilt University Medical Center (VUMC) privacy office within 7 days of discovery.
Study Withdrawal/discontinuation Participants may withdraw at any time by providing written intent to the Primary Investigator. Participants may be removed from the study if they develop a major surgical complication after their cesarean.
Statistical Considerations
Using prior data, the average opioid MME used per person was 130 MME (SD 90) in the "average use" group. With an alpha of 5% and a beta of 80%, we estimate that 160 total participants are required to show a 30% reduction in opioid used. Assuming a lost to follow up rate of 20%, we plan to enroll 200 women.
Follow-up and Record Retention On average 100 cesareans are performed per month. With a 50% enrollment rate, we anticipate this study will take 4 months to complete
The patient list will be destroyed upon data analysis and publication. Redcap will be archived upon publication.
- Conditions
- Opioid Use
- Being tested
- Opioid Education Handout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Opioid Education HandoutOther
a single page handout with information about how to use medications for pain after discharge.
| Study group | Role | What they receive |
|---|---|---|
| Education | Experimental | Opioid Education Receives: Other: Opioid Education Handout |
| Control | No intervention | standard discharge instructions, which lists medications prescribed at discharge |
What is being measured
The primary outcome is the main question the study is designed to answer.
Opioid Use
Median number of tablets of hydrocodone-acetaminophen used after hospital discharge
Measured: 6 weeks postpartum
Secondary outcomes (3)
Disposed of Opioids Correctly
Frequency of women reporting that they either returned their unused opioids to a pharmacy or flushed them down the toilet
Measured: 6 weeks postpartum
Analgesic Quiz Score
Median score on an assessment of characteristics of analgesics including side effects, risks, and benefits. Score 1-10 for each question. Higher score is better.
Measured: 6 weeks postpartum
Additional Prescriptions
Percentage of patients obtaining additional prescriptions for pain
Measured: 6 weeks postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2018
- Study start1 Sep 2018
- Primary completion1 Feb 2019
- Study completion1 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Opioid UseStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 196 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sarah Osmundson, Vanderbilt University Medical Center
- Investigators
- Sarah Osmundson, MD, Principal investigator, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03678870
- Sponsor's protocol ID
- 181190
- Status last verified
- Feb 2020
- First submitted
- 18 Sep 2018
- Last updated
- 17 Feb 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Schirle LM, Dietrich MS, Lam L, Stone AL, Bruehl S, Osmundson SS. Accuracy of patient-reported versus real-time electronic postoperative opioid use outcomes. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100347. doi: 10.1016/j.ajogmf.2021.100347. Epub 2021 Mar 11. No abstract available.
PubMed 33716134Lam L, Richardson MG, Zhao Z, Thampy M, Ha L, Osmundson SS. Enhanced discharge counseling to reduce outpatient opioid use after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100286. doi: 10.1016/j.ajogmf.2020.100286. Epub 2020 Dec 3.
PubMed 33451618
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Discharge Opioid Education to Decrease Opioid Use After Cesarean
- ClinicalTrials.gov ID
- NCT03678870
- Acronym / sponsor ID
- 181190
- Conditions
- Opioid Use
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 196 participants (actual)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 1 Sep 2018 (actual)
- Primary completion
- 1 Feb 2019 (actual)
- Study completion
- 1 Nov 2019 (actual)
- First posted
- 20 Sep 2018 (actual)
- Results
- Posted 5 Feb 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.
Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge
Detailed description
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.
Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge
Preliminary Data: Our soon to be published study (Obstetrics \& Gynecology Journal) found that 30% of women used all their opioids after discharge for cesarean delivery because they "were following directions" and not because they had pain.
Enrollment \& Randomization
Enrollment
- Participants will be approached after their cesarean delivery either in the recovery room or in their private postpartum room
- Informed written consent will be obtained by a trained research assistant (i.e. medical student) or by the study researchers (Attendings, fellows)
- After enrollment, participants will be asked to complete Survey 1 either in person or by giving sending them the web link with RedCap
Randomization
- Enrolled patients will be randomized in a 1:1 ratio using permuted blocks of 6
- Randomization sequence will be developed through sealed envelope.com
- Randomization and allocation will be done through RedCap
Study Procedures
- Enrollment
- Postoperative Day 0-1: Survey 1 through RedCap (takes ~10 minutes)
- Randomization education versus usual care
- Control = Standard discharge instructions, which list medications prescribed at discharge
- Intervention = a single page handout (see attachment) with information about how to use medications for pain after discharge. This handout contains the following instructions
- Get baseline pain control with ibuprofen
- Use your opioid prescription only if your pain is very bad
- Taper your medications
- Get rid of leftover opioid tablets
- At discharge all patients will receive the follow medications using PillsyCaps. These are standard medications given at discharge at our institution
- Ibuprofen 600mg: 30 tablets
- Hydrocodone 5mg -acetaminophen 325mg: 30 tablets
- Postoperative day 14: All participants will be contacted to complete Survey 2 (Takes ~ 15 minutes
- Attempts to contact each participant will be done 3 times before they are designated as "lost to follow up"
- If a participant is still using opioids on postoperative day 14, they should be contacted weekly until they are no longer taking opioids
Primary Outcome Median number of tablets of hydrocodone-acetaminophen used after hospital discharge
Secondary Outcomes:
- Visual Analog Scale pain score (median)
- Percentage of patients reporting pain since discharge as worse than expected
- Percentage of patients obtaining additional prescriptions for pain
- Percentage of patients with unscheduled visits for pain
- Mean ibuprofen milligrams used hours 24-47 after cesarean
- Mean acetaminophen milligrams used hours 24-47 after cesarean
- Total Morphine Milligram Equivalents (MME) used per hour of inpatient stay
Risks
- Breach of confidentiality of protected health information
Reporting Adverse Events Any adverse events or unanticipated problems involving risk to participants or others will be reported to the Institutional Review Board and the Vanderbilt University Medical Center (VUMC) privacy office within 7 days of discovery.
Study Withdrawal/discontinuation Participants may withdraw at any time by providing written intent to the Primary Investigator. Participants may be removed from the study if they develop a major surgical complication after their cesarean.
Statistical Considerations
Using prior data, the average opioid MME used per person was 130 MME (SD 90) in the "average use" group. With an alpha of 5% and a beta of 80%, we estimate that 160 total participants are required to show a 30% reduction in opioid used. Assuming a lost to follow up rate of 20%, we plan to enroll 200 women.
Follow-up and Record Retention On average 100 cesareans are performed per month. With a 50% enrollment rate, we anticipate this study will take 4 months to complete
The patient list will be destroyed upon data analysis and publication. Redcap will be archived upon publication.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Education | Experimental | Other: Opioid Education HandoutOpioid Education |
| Control | No intervention | –standard discharge instructions, which lists medications prescribed at discharge |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Women 18-45 years old
- Women undergoing cesarean delivery at VUMC
Key exclusion criteria (4 listed)
- Major post-surgical complications:
- cesarean hysterectomy, bowel or bladder injury, reoperation, ICU admission, wound infection or separation
- Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for > 7 days during pregnancy.
- Women who do not speak English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Opioid Education Handouta single page handout with information about how to use medications for pain after discharge. | Other | Education |
Primary outcome
Opioid Use
Time frame: 6 weeks postpartum
Median number of tablets of hydrocodone-acetaminophen used after hospital discharge
3 secondary outcomes
Disposed of Opioids Correctly
Time frame: 6 weeks postpartum
Analgesic Quiz Score
Time frame: 6 weeks postpartum
Additional Prescriptions
Time frame: 6 weeks postpartum
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33716134Schirle LM, Dietrich MS, Lam L, Stone AL, Bruehl S, Osmundson SS. Accuracy of patient-reported versus real-time electronic postoperative opioid use outcomes. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100347. doi: 10.1016/j.ajogmf.2021.100347. Epub 2021 Mar 11. No abstract available.
- Derived from this study: PubMed 33451618Lam L, Richardson MG, Zhao Z, Thampy M, Ha L, Osmundson SS. Enhanced discharge counseling to reduce outpatient opioid use after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100286. doi: 10.1016/j.ajogmf.2020.100286. Epub 2020 Dec 3.
- Individual participant dataSharing planned: No
Related trials for Opioid Use
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
RecruitingPhase 4
Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures
Opioid Use, Fractures, Bone
Enrolling by invitation
PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial)
Burnout, Secondary Trauma
Not yet recruiting
Real World Evaluation of the Effectiveness and Implementation of a Digital Health Therapeutic for OUD
Opioid Use Disorder
Not yet recruitingEarly Phase 1
Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
Opioid Use Disorder, Alcohol Intoxication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah Osmundson, MD principal investigator
Vanderbilt University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Opioid Education Handout in people with Opioid Use, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Opioid Use (time frame: 6 weeks postpartum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03678870, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2020.